4/A//SEC Filing
Williams Lewis T 4/A
Accession 0001209191-19-014685
CIK 0001175505other
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 6:15 PM ET
Size
8.3 KB
Accession
0001209191-19-014685
Insider Transaction Report
Form 4/AAmended
Williams Lewis T
DirectorPresident and CEO
Transactions
- Award
Common Stock
2019-02-25+1,000→ 462,360 total - Award
Employee Stock Option (right to buy)
2019-02-25+6,400→ 6,400 totalExercise: $11.97Exp: 2029-02-24→ Common Stock (6,400 underlying)
Footnotes (4)
- [F1]Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 25, 2020, 2021 and 2022, provided the reporting person provides services to Five Prime Therapeutics, Inc. (the "Company") through each such date.
- [F2]This amendment is being filed to reflect the grant to the reporting person of (i) 1,000 shares of restricted common stock of the Company and (ii) 6,400 options to purchase shares of common stock of the Company, each of which was inadvertently omitted from the reporting person's original Form 4 filed with the Securities and Exchange Commission (the "SEC") on February 27, 2019.
- [F3]Reflects the holdings of the reporting person as of the date of the original Form 4 filed with the SEC on February 27, 2019, taking into account the transaction set forth in such original Form 4 and the transaction set forth in this amendment.
- [F4]The shares underlying the option vest at a rate of one forty-eighth (1/48) per month following February 25, 2019, provided the reporting person provides services to the Company through each such date.
Documents
Issuer
FIVE PRIME THERAPEUTICS INC
CIK 0001175505
Entity typeother
Related Parties
1- filerCIK 0001475714
Filing Metadata
- Form type
- 4/A
- Filed
- Feb 27, 7:00 PM ET
- Accepted
- Feb 28, 6:15 PM ET
- Size
- 8.3 KB